Infection and Atherosclerosis Development

O'Connor, 2001, Potential infectious etiologies of atherosclerosis: a multifactorial perspective, Emerg Infect Dis, 7, 780, 10.3201/eid0705.010503

Rosenfeld, 2011, Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis, Thromb Haemost, 106, 858, 10.1160/TH11-06-0392

Kuo, 1993, Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries, J Infect Dis, 167, 841, 10.1093/infdis/167.4.841

Campbell, 1995, Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues, J Infect Dis, 172, 585, 10.1093/infdis/172.2.585

Shor, 1992, Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques, S Afr Med J, 82, 158

Chiu, 1999, Multiple infections in carotid atherosclerotic plaques, Am Heart J, 138, S534, 10.1016/S0002-8703(99)70294-2

Ford, 2006, Inflammation, heat shock proteins and periodontal pathogens in atherosclerosis: an immunohistologic study, Oral Microbiol Immunol, 21, 206, 10.1111/j.1399-302X.2006.00276.x

Haraszthy, 2000, Identification of periodontal pathogens in atheromatous plaques, J Periodontol, 71, 1554, 10.1902/jop.2000.71.10.1554

Padilla, 2006, Periodontal pathogens in atheromatous plaques isolated from patients with chronic periodontitis, J Periodontal Res, 41, 350, 10.1111/j.1600-0765.2006.00882.x

Ameriso, 2001, Detection of Helicobacter pylori in human carotid atherosclerotic plaques, Stroke, 32, 385, 10.1161/01.STR.32.2.385

Ghirardi, 2006, Helicobacter pylori detected in atheroma plaque, Rev Fac Cien Med Univ Nac Cordoba, 63, 17

Kowalski, 2001, J Physiol Pharmacol, 52, 3

Adiloglu, 2005, Detection of Helicobacter pylori and Chlamydia pneumoniae DNA in human coronary arteries and evaluation of the results with serologic evidence of inflammation, Saudi Med J, 26, 1068

Reszka, 2008, Detection of infectious agents by polymerase chain reaction in human aortic wall, Cardiovasc Pathol, 17, 297, 10.1016/j.carpath.2007.11.002

Latsios, 2004, Detection of cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae DNA in carotid atherosclerotic plaques by the polymerase chain reaction, Acta Cardiol, 59, 652, 10.2143/AC.59.6.2005249

Nakano, 2006, Detection of cariogenic Streptococcus mutans in extirpated heart valve and atheromatous plaque specimens, J Clin Microbiol, 44, 3313, 10.1128/JCM.00377-06

Kozarov, 2006, Detection of bacterial DNA in atheromatous plaques by quantitative PCR, Microbes Infect, 8, 687, 10.1016/j.micinf.2005.09.004

Pucar, 2007, Correlation between atherosclerosis and periodontal putative pathogenic bacterial infections in coronary and internal mammary arteries, J Periodontol, 78, 677, 10.1902/jop.2007.060062

Melnick, 1994, Cytomegalovirus DNA in arterial walls of patients with atherosclerosis, J Med Virol, 42, 170, 10.1002/jmv.1890420213

Horvath, 2000, The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis, J Clin Virol, 16, 17, 10.1016/S1386-6532(99)00064-5

Radke, 2001, Infectious agents in coronary lesions obtained by endatherectomy: pattern of distribution, coinfection, and clinical findings, Coron Artery Dis, 12, 1, 10.1097/00019501-200102000-00001

Lin, 2003, Increased incidence of cytomegalovirus but not Chlamydia pneumoniae in atherosclerotic lesions of arteries of lower extremities from patients with diabetes mellitus undergoing amputation, J Clin Pathol, 56, 429, 10.1136/jcp.56.6.429

Kwon, 2004, Detection of enterovirus, cytomegalovirus, and Chlamydia pneumoniae in atheromas, J Microbiol, 42, 299

Ibrahim, 2005, Detection of herpes simplex virus, cytomegalovirus and Epstein-Barr virus DNA in atherosclerotic plaques and in unaffected bypass grafts, J Clin Virol, 32, 29, 10.1016/j.jcv.2004.06.010

Liu, 2006, Presence and severity of Chlamydia pneumoniae and cytomegalovirus infection in coronary plaques are associated with acute coronary syndromes, Int Heart J, 47, 511, 10.1536/ihj.47.511

Virok, 2006, Chlamydophila pneumoniae and human cytomegalovirus in atherosclerotic carotid plaques–combined presence and possible interactions, Acta Microbiol Immunol Hung, 53, 35, 10.1556/AMicr.53.2006.1.3

Boddi, 2010, Hepatitis C virus RNA localization in human carotid plaques, J Clin Virol, 47, 72, 10.1016/j.jcv.2009.10.005

Eugenin, 2008, Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease, Am J Pathol, 172, 1100, 10.2353/ajpath.2008.070457

Jha, 2009, Prevalence of Chlamydophila pneumoniae is higher in aorta and coronary artery than in carotid artery of coronary artery disease patients, APMIS, 117, 905, 10.1111/j.1600-0463.2009.02553.x

Hagiwara, 2007, Lack of association between infectious burden and carotid atherosclerosis in Japanese patients, J Stroke Cerebrovasc Dis, 16, 145, 10.1016/j.jstrokecerebrovasdis.2007.02.001

Benditt, 1983, Viruses in the etiology of atherosclerosis, Proc Natl Acad Sci U S A, 80, 6386, 10.1073/pnas.80.20.6386

Muller, 2005, Chlamydia pneumoniae, herpes simplex virus and cytomegalovirus in symptomatic and asymptomatic high-grade internal carotid artery stenosis. Does infection influence plaque stability?, Vasa, 34, 163, 10.1024/0301-1526.34.3.163

Shi, 2002, Chlamydia pneumoniae and multiple infections in the aorta contribute to atherosclerosis, Pathol Int, 52, 755, 10.1046/j.1440-1827.2002.01422.x

Liu, 2009, Human parvovirus b19 infection in patients with coronary atherosclerosis, Arch Med Res, 40, 612, 10.1016/j.arcmed.2009.09.002

Ramirez, 1996, Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group, Ann Intern Med, 125, 979, 10.7326/0003-4819-125-12-199612150-00008

Jackson, 1997, Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen, J Infect Dis, 176, 292, 10.1086/517270

Maass, 1998, Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease, J Am Coll Cardiol, 31, 827, 10.1016/S0735-1097(98)00016-3

Rafferty, 2011, Cultivation of Enterobacter hormaechei from human atherosclerotic tissue, J Atheroscler Thromb, 18, 72, 10.5551/jat.5207

Kozarov, 2005, Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, Arterioscler Thromb Vasc Biol, 25, e17, 10.1161/01.ATV.0000155018.67835.1a

Fabricant, 1978, Virus-induced atherosclerosis, J Exp Med, 148, 335, 10.1084/jem.148.1.335

Fabricant, 1983, Herpesvirus-induced atherosclerosis in chickens, Fed Proc, 42, 2476

Kuo, 1995, Chlamydia pneumoniae (TWAR), Clin Microbiol Rev, 8, 451, 10.1128/CMR.8.4.451

Yang, 1993, A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis, Infect Immun, 61, 2037, 10.1128/IAI.61.5.2037-2040.1993

Blessing, 2001, Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice, Atherosclerosis, 158, 13, 10.1016/S0021-9150(00)00758-9

Hu, 1999, The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae, J Clin Invest, 103, 747, 10.1172/JCI4582

Moazed, 1999, Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice, J Infect Dis, 180, 238, 10.1086/314855

Muhlestein, 2011, Chronic infection and coronary atherosclerosis. Will the hypothesis ever really pan out?, J Am Coll Cardiol, 58, 2007, 10.1016/j.jacc.2011.08.015

Sorrentino, 2015, A single infection with Chlamydia pneumoniae is sufficient to exacerbate atherosclerosis in ApoE deficient mice, Cell Immunol, 294, 25, 10.1016/j.cellimm.2015.01.007

Fong, 1999, De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model, Infect Immun, 67, 6048, 10.1128/IAI.67.11.6048-6055.1999

Blessing, 2000, Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice, Infect Immun, 68, 4765, 10.1128/IAI.68.8.4765-4768.2000

Blessing, 2002, Chlamydia pneumoniae and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice, Infect Immun, 70, 5332, 10.1128/IAI.70.9.5332-5334.2002

Ezzahiri, 2002, Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice, Cardiovasc Res, 56, 269, 10.1016/S0008-6363(02)00544-8

Campbell, 2005, Tumor necrosis factor alpha plays a role in the acceleration of atherosclerosis by Chlamydia pneumoniae in mice, Infect Immun, 73, 3164, 10.1128/IAI.73.5.3164-3165.2005

Chen, 2010, IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice, J Immunol, 185, 5619, 10.4049/jimmunol.1001879

Chen, 2008, Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation, J Immunol, 181, 7186, 10.4049/jimmunol.181.10.7186

Naiki, 2005, MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia, J Biol Chem, 280, 29242, 10.1074/jbc.M503225200

Chesebro, 2003, Nitric oxide synthase plays a role in Chlamydia pneumoniae-induced atherosclerosis, Cardiovasc Res, 60, 170, 10.1016/S0008-6363(03)00389-4

Kataoka, 1999, Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions, Circulation, 99, 3110, 10.1161/01.CIR.99.24.3110

Kume, 1998, Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells, Circ Res, 83, 322, 10.1161/01.RES.83.3.322

Moriwaki, 1998, Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha, FEBS Lett, 440, 29, 10.1016/S0014-5793(98)01414-8

Sawamura, 1997, An endothelial receptor for oxidized low-density lipoprotein, Nature, 386, 73, 10.1038/386073a0

Li, 2003, LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells, Circulation, 107, 612, 10.1161/01.CIR.0000047276.52039.FB

Li, 2000, Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells, Circulation, 101, 2889, 10.1161/01.CIR.101.25.2889

Zhu, 2005, Ox-LDL plays dual effect in modulating expression of inflammatory molecules through LOX-1 pathway in human umbilical vein endothelial cells, Front Biosci, 10, 2585, 10.2741/1722

Campbell, 2013, Chlamydia pneumoniae induces expression of pro-atherogenic factors through activation of the lectin-like oxidized LDL receptor-1, Pathog Dis, 10.1111/2049-632X.12058

Campbell, 2012, Chlamydia pneumoniae binds to the lectin-like oxidized LDL receptor for infection of endothelial cells, Microbes Infect, 14, 43, 10.1016/j.micinf.2011.08.003

Yoshida, 2006, Chlamydia pneumoniae infection enhances lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression on human endothelial cells, FEMS Microbiol Lett, 260, 17, 10.1111/j.1574-6968.2006.00286.x

Campbell LA, Berrry MW, Heard J, et al. Chlamydia pneumoniae induces expression of the scavenger receptor LOX-1 and proatherogenic factors in C57BL/6J mice. Chlamydial Infections Proceedings of the 12th International Symposium on Human Chlamydial Infections. In: Schacter J et al. San Francisco, CA: The International Chlamydia Symposium. 2010. pp. 161–164.

Campbell, 2010, The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis, Microbes Infect, 12, 598, 10.1016/j.micinf.2010.04.001

Naiki, 2008, TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis, J Immunol, 181, 7176, 10.4049/jimmunol.181.10.7176

Ezzahiri, 2006, Chlamydia pneumoniae infections augment atherosclerotic lesion formation: a role for serum amyloid P, APMIS, 114, 117, 10.1111/j.1600-0463.2006.apm_205.x

Van Lenten, 2001, High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection, Circulation, 103, 2283, 10.1161/01.CIR.103.18.2283

Blessing, 2005, A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae, J Antimicrob Chemother, 55, 1037, 10.1093/jac/dki128

Rothstein, 2001, Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae, J Infect Dis, 183, 232, 10.1086/317941

Muhlestein, 1998, Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model, Circulation, 97, 633, 10.1161/01.CIR.97.7.633

Fong, 2002, Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model, Antimicrob Agents Chemother, 46, 2321, 10.1128/AAC.46.8.2321-2326.2002

Ezzahiri, 2003, Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice, Eur J Vasc Endovasc Surg, 26, 88, 10.1053/ejvs.2002.1913

McGorisk, 1996, Endothelial dysfunction in coronary heart disease, Curr Opin Cardiol, 11, 341, 10.1097/00001573-199607000-00002

Liuba, 2000, Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice, Circulation, 102, 1039, 10.1161/01.CIR.102.9.1039

Liuba, 2003, Co-infection with Chlamydia pneumoniae and Helicobacter pylori results in vascular endothelial dysfunction and enhanced VCAM-1 expression in apoE-knockout mice, J Vasc Res, 40, 115, 10.1159/000070708

Liuba, 2003, Acute Chlamydia pneumoniae infection causes coronary endothelial dysfunction in pigs, Atherosclerosis, 167, 215, 10.1016/S0021-9150(03)00019-4

Pihlstrom, 2005, Periodontal diseases, Lancet, 366, 1809, 10.1016/S0140-6736(05)67728-8

Li, 2002, Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model, Circulation, 105, 861, 10.1161/hc0702.104178

Lalla, 2003, Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice, Arterioscler Thromb Vasc Biol, 23, 1405, 10.1161/01.ATV.0000082462.26258.FE

Champagne, 2009, Gender differences in systemic inflammation and atheroma formation following Porphyromonas gingivalis infection in heterozygous apolipoprotein E-deficient mice, J Periodontal Res, 44, 569, 10.1111/j.1600-0765.2008.01156.x

Madan, 2007, Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: cytokine profiling implications, Atherosclerosis, 190, 62, 10.1016/j.atherosclerosis.2006.02.026

Amar, 2009, Is Porphyromonas gingivalis cell invasion required for atherogenesis? Pharmacotherapeutic implications, J Immunol, 182, 1584, 10.4049/jimmunol.182.3.1584

Koizumi, 2008, Nasal immunization with Porphyromonas gingivalis outer membrane protein decreases P. gingivalis-induced atherosclerosis and inflammation in spontaneously hyperlipidemic mice, Infect Immun, 76, 2958, 10.1128/IAI.01572-07

Lucas, 2014, Myxomavirus anti-inflammatory chemokine binding protein reduces the increased plaque growth induced by chronic Porphyromonas gingivalis oral infection after balloon angioplasty aortic injury in mice, PLoS One, 9, e111353, 10.1371/journal.pone.0111353

Jain, 2003, Role for periodontitis in the progression of lipid deposition in an animal model, Infect Immun, 71, 6012, 10.1128/IAI.71.10.6012-6018.2003

Hasturk, 2015, Resolvin E1 attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis, Arterioscler Thromb Vasc Biol, 5, 1123, 10.1161/ATVBAHA.115.305324

De Nardo, 2011, NLRP3 inflammasomes link inflammation and metabolic disease, Trends Immunol, 32, 373, 10.1016/j.it.2011.05.004

Latz, 2013, Activation and regulation of the inflammasomes, Nat Rev Immunol, 13, 397, 10.1038/nri3452

Yamaguchi, 2015, Activation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated atherosclerosis, Pathog Dis, 73, 10.1093/femspd/ftv011

Bostanci, 2012, Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen, FEMS Microbiol Lett, 333, 1, 10.1111/j.1574-6968.2012.02579.x

Kramer, 2014, Distinct gene signatures in aortic tissue from ApoE–/– mice exposed to pathogens or Western diet, BMC Genomics, 15, 1176, 10.1186/1471-2164-15-1176

Jia, 2013, Periodontal pathogen accelerates lipid peroxidation and atherosclerosis, J Dent Res, 92, 247, 10.1177/0022034513475625

Jia, 2015, Aggregatibacter actinomycetemcomitans induces Th17 cells in atherosclerotic lesions, Pathog Dis, 73, 10.1093/femspd/ftu027

Gao, 2010, A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice, J Immunol, 185, 5820, 10.4049/jimmunol.1000116

Taleb, 2009, Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis, J Exp Med, 206, 2067, 10.1084/jem.20090545

Chukkapalli, 2015, Chronic oral infection with major periodontal bacteria Tannerella forsythia modulates systemic atherosclerosis risk factors and inflammatory markers, Pathog Dis, 73, 10.1093/femspd/ftv009

Wroblewski, 2010, Helicobacter pylori and gastric cancer: factors that modulate disease risk, Clin Microbiol Rev, 23, 713, 10.1128/CMR.00011-10

Chen, 2010, Helicobacter pylori infection enhances atherosclerosis in high-cholesterol diet fed C57BL/6 mice, Zhonghua Xin Xue Guan Bing Za Zhi, 38, 259

Mach, 2002, Influence of Helicobacter pylori infection during atherogenesis in vivo in mice, Circ Res, 90, E1, 10.1161/hh0102.102270

Ayada, 2007, Chronic infections and atherosclerosis, Ann N Y Acad Sci, 1108, 594, 10.1196/annals.1422.062

Ayada, 2009, Regulation of cellular immunity prevents Helicobacter pylori-induced atherosclerosis, Lupus, 18, 1154, 10.1177/0961203309106600

Weller, 1971, The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I, N Engl J Med, 285, 203, 10.1056/NEJM197107222850406

Weller, 1971, The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. II, N Engl J Med, 285, 267, 10.1056/NEJM197107292850507

Fateh-Moghadam, 2003, Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy, Transplantation, 76, 1470, 10.1097/01.TP.0000090163.48433.48

Grattan, 1989, Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis, JAMA, 261, 3561, 10.1001/jama.1989.03420240075030

Chen, 2003, The relationship between human cytomegalovirus infection and atherosclerosis development, Mol Cell Biochem, 249, 91, 10.1023/A:1024759311013

Burnett, 2001, Atherosclerosis in apoE knockout mice infected with multiple pathogens, J Infect Dis, 183, 226, 10.1086/317938

Hsich, 2001, Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice, Atherosclerosis, 156, 23, 10.1016/S0021-9150(00)00608-0

Vliegen, 2005, Mouse cytomegalovirus antigenic immune stimulation is sufficient to aggravate atherosclerosis in hypercholesterolemic mice, Atherosclerosis, 181, 39, 10.1016/j.atherosclerosis.2004.12.035

Vliegen, 2004, Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation, Microbes Infect, 6, 17, 10.1016/j.micinf.2003.09.024

Tang-Feldman, 2013, Murine cytomegalovirus (MCMV) infection upregulates P38 MAP kinase in aortas of Apo E KO mice: a molecular mechanism for MCMV-induced acceleration of atherosclerosis, J Cardiovasc Transl Res, 6, 54, 10.1007/s12265-012-9428-x

Warren-Gash, 2009, Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review, Lancet Infect Dis, 9, 601, 10.1016/S1473-3099(09)70233-6

Haidari, 2010, Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice, Atherosclerosis, 208, 90, 10.1016/j.atherosclerosis.2009.07.028

Bainton, 1978, Influenza and ischaemic heart disease–a possible trigger for acute myocardial infarction?, Int J Epidemiol, 7, 231, 10.1093/ije/7.3.231

Abinader, 1993, Inferior wall myocardial infarction preceded by acute exudative pharyngitis in young males, Isr J Med Sci, 29, 764

Naghavi, 2003, Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice, Circulation, 107, 762, 10.1161/01.CIR.0000048190.68071.2B

Grayston, 2003, Antibiotic treatment of atherosclerotic cardiovascular disease, Circulation, 107, 1228, 10.1161/01.CIR.0000056032.56396.89

O'Connor, 2003, Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial, JAMA, 290, 1459, 10.1001/jama.290.11.1459

Grayston, 2005, Azithromycin for the secondary prevention of coronary events, N Engl J Med, 352, 1637, 10.1056/NEJMoa043526

Cannon, 2005, Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome, N Engl J Med, 352, 1646, 10.1056/NEJMoa043528

Jespersen, 2006, Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial, BMJ, 332, 22, 10.1136/bmj.38666.653600.55

Joensen, 2008, Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial, Atherosclerosis, 196, 937, 10.1016/j.atherosclerosis.2007.02.025

Jaff, 2009, Circulation, 119, 452, 10.1161/CIRCULATIONAHA.108.815308

Grayston, 2015, Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested, Pathog Dis, 73, 1, 10.1093/femspd/ftu015

Grayston JTB, Belland RJ, Byrne GI, Kuo CC, Schachter J, Stamm WE, Ahong G. Infection with Chlamydia pneumoniae as a cause of coronary heart diesase: the hypothesis is still untested. Proc 13th International Sympositum of Human Chlamydial Infections, Schachter J, et al. San Franciso, CA: The International Chlamydia Symposium. 2014. pp. 507–512.

Anderson, 2005, Infection, antibiotics, and atherothrombosis–end of the road or new beginnings?, N Engl J Med, 352, 1706, 10.1056/NEJMe058019

Taylor-Robinson, 2005, The failure of antibiotics to prevent heart attacks, BMJ, 331, 361, 10.1136/bmj.331.7513.361

Deniset, 2010, Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis, Fundam Clin Pharmacol, 24, 607, 10.1111/j.1472-8206.2010.00863.x

Campbell, 2014, Persistent C. pneumoniae infection in atherosclerotic lesions: rethinking the clinical trials, Front Cell Infect Microbiol, 4, 34, 10.3389/fcimb.2014.00034

Beatty, 1994, Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease, Trends Microbiol, 2, 94, 10.1016/0966-842X(94)90542-8

Carter, 2010, Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial, Arthritis Rheum, 62, 1298, 10.1002/art.27394

Epstein, 2009, Insights into the role of infection in atherogenesis and in plaque rupture, Circulation, 119, 3133, 10.1161/CIRCULATIONAHA.109.849455

Elizalde, 2004, Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes, Helicobacter, 9, 681, 10.1111/j.1083-4389.2004.00271.x

Murdin, 2000, Collaborative multidisciplinary workshop report: progress toward a Chlamydia pneumoniae vaccine, J Infect Dis, 181 Suppl 3, S552, 10.1086/315601

Eddens, 2012, Effect of age and vaccination on extent and spread of Chlamydia pneumoniae infection in C57BL/6 mice, Immun Ageing, 9, 11, 10.1186/1742-4933-9-11

Glezen, 1987, Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978–1981, Am Rev Respir Dis, 136, 550, 10.1164/ajrccm/136.3.550

Thompson, 2004, Influenza-associated hospitalizations in the United States, JAMA, 292, 1333, 10.1001/jama.292.11.1333

Davis, 2006, Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology, Circulation, 114, 1549, 10.1161/CIRCULATIONAHA.106.178242

Ciszewski, 2008, Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study, Eur Heart J, 29, 1350, 10.1093/eurheartj/ehm581

Nichol, 2003, Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly, N Engl J Med, 348, 1322, 10.1056/NEJMoa025028

Gurfinkel, 2002, Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study, Circulation, 105, 2143, 10.1161/01.CIR.0000016182.85461.F4

Gurfinkel, 2004, Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry, Tex Heart Inst J, 31, 28

Gurfinkel, 2004, Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study, Eur Heart J, 25, 25, 10.1016/j.ehj.2003.10.018

Phrommintikul, 2011, Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome, Eur Heart J, 32, 1730, 10.1093/eurheartj/ehr004

Loomba, 2012, Influenza vaccination and cardiovascular morbidity and mortality: analysis of 292,383 patients, J Cardiovasc Pharmacol Ther, 17, 277, 10.1177/1074248411429965

Udell, 2013, Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis, JAMA, 310, 1711, 10.1001/jama.2013.279206

Goeijenbier, 2012, Review: Viral infections and mechanisms of thrombosis and bleeding, J Med Virol, 84, 1680, 10.1002/jmv.23354

Bermudez-Fajardo, 2011, Influenza vaccination promotes stable atherosclerotic plaques in apoE knockout mice, Atherosclerosis, 217, 97, 10.1016/j.atherosclerosis.2011.03.019

Veljkovic, 2014, Influenza vaccine as prevention for cardiovascular diseases: possible molecular mechanism, Vaccine, 32, 6569, 10.1016/j.vaccine.2014.07.007